Currently, there are no regulations specifically regarding investigational tobacco products. As such, at this time they are not exempt from requirements stated in the FD&C Act. Last week, FDA released a draft guidance that “discusses the kind of information FDA intends to consider in making enforcement decisions regarding the use of investigational tobacco products until regulations are issued and become effective or FDA provides written notice of its intent to change its enforcement policy.” While this is not the first draft guidance discussing investigational tobacco products (two others have been published, including Applications for Premarket Review of New Tobacco Products (September 2011); and Modified Risk Tobacco Product Applications (March 30 2012)), when finalized, the recently released document will provide the most in-depth and detailed recommendations from the Agency regarding these products.
According to Section 910(g) of the Food, Drug, & Cosmetic Act, “The Secretary may exempt tobacco products intended for investigational use from the provisions of this chapter under such conditions as the Secretary may by regulation prescribe.” Additionally, this section requires that any “new tobacco product” undergo premarket review. FDA intends to exempt certain investigational tobacco products from these requirements under certain [ pre-determined ] conditions.
According to the draft guidance, FDA intends to consider the following information in making enforcement decisions regarding the use of investigational tobacco products in nonclinical laboratory studies:
The document also provides information and recommendations regarding studies conducted outside the US, preparation and maintenance of study records, submitting information for the proposed use of an investigational tobacco product, and requesting meetings with FDA. In summation, the overall purpose of the guidance is discusses the type of information FDA intends to consider in making enforcement decisions regarding the use of investigational tobacco products in the US.
The Agency released the guidance for comment purposes only, and is asking people within the industry to submit their comments on the draft within 60 days of being published (by November 23, 2015). For more information and details, view the full guidance here.
Do you have a tobacco product that is either developed or still in the process of being developed? Assuring you are compliant with the FDA regulations on these products can be tricky, but that is why we are here to help. We have a history of working with various tobacco and e-cigarette products, and using our unique approach that combines scientific knowledge with regulatory expertise, we have been able to successfully help our clients get through FDA. To learn more about our tobacco and e-cigarette services or for more information on how we can help you, please contact us.
August 8, 2019
Over-the-counter (OTC) drugs are defined by the FDA as drugs that are safe and effective for use by the general public without seeking treatment by a health professional. Currently, there are more...
April 27, 2022
Guidance for Industry April 21, 2022 Nanotechnology can be used in a broad array of FDA-regulated products, such as human drug products, including those that are biological products.3 Nanotechnology...
April 6, 2020
On Wednesday, April 1, 2020, FDA issued a statement asking all companies to stop selling all forms of Zantac (ranitidine). Background On Friday, September 13, 2019, the FDA announced that “some...